Literature DB >> 22252554

c-Src and IL-6 inhibit osteoblast differentiation and integrate IGFBP5 signalling.

Barbara Peruzzi1, Alfredo Cappariello, Andrea Del Fattore, Nadia Rucci, Fabrizio De Benedetti, Anna Teti.   

Abstract

Interleukin-6 (IL-6) and c-Src impair osteoblast maturation in vitro and in vivo. Given the similar effects of these factors, they are likely to establish a functional loop to maintain osteoblasts in a less mature status. Here we describe a pathway whereby c-Src stimulates IL-6 expression through the STAT3 factor, which, in response to IL-6 induces insulin-like growth factor 5 (IGFBP5), a c-Src activating factor that amplifies this loop only in immature osteoblasts. In contrast, in mature osteoblasts, IGFBP5 is enhanced by Runx2, but is no longer able to stimulate c-Src activation, as this tyrosine kinase at this stage is downregulated. We find that the IGFBP5 produced by osteoblasts stimulates osteoclastogenesis and bone resorption, acting as an osteoblast-osteoclast coupling factor. Finally, we demonstrate that the integrated actions of c-Src, IL-6 and IGFBP5 also have a role in vivo. We conclude that this pathway is relevant for bone metabolism, both in physiological and in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22252554     DOI: 10.1038/ncomms1651

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  29 in total

Review 1.  Interleukin-6: An osteotropic factor influencing bone formation?

Authors:  Nathalie Franchimont; Sylvie Wertz; Michel Malaise
Journal:  Bone       Date:  2005-08-19       Impact factor: 4.398

2.  Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation.

Authors:  S Kotake; K Sato; K J Kim; N Takahashi; N Udagawa; I Nakamura; A Yamaguchi; T Kishimoto; T Suda; S Kashiwazaki
Journal:  J Bone Miner Res       Date:  1996-01       Impact factor: 6.741

3.  Tartronates: a new generation of drugs affecting bone metabolism.

Authors:  G Caselli; M Mantovanini; C A Gandolfi; M Allegretti; S Fiorentino; L Pellegrini; G Melillo; R Bertini; W Sabbatini; R Anacardio; G Clavenna; G Sciortino; A Teti
Journal:  J Bone Miner Res       Date:  1997-06       Impact factor: 6.741

4.  The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice.

Authors:  E Gyotoku; E Morita; Y Kameyoshi; T Hiragun; S Yamamoto; M Hide
Journal:  Arch Dermatol Res       Date:  2001-11       Impact factor: 3.017

5.  Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses.

Authors:  S J Rodig; M A Meraz; J M White; P A Lampe; J K Riley; C D Arthur; K L King; K C Sheehan; L Yin; D Pennica; E M Johnson; R D Schreiber
Journal:  Cell       Date:  1998-05-01       Impact factor: 41.582

6.  Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma.

Authors:  Y Su; E R Wagner; Q Luo; J Huang; L Chen; B-C He; G-W Zuo; Q Shi; B-Q Zhang; G Zhu; Y Bi; J Luo; X Luo; S H Kim; J Shen; F Rastegar; E Huang; Y Gao; J-L Gao; K Yang; C Wietholt; M Li; J Qin; R C Haydon; T-C He; H H Luu
Journal:  Oncogene       Date:  2011-04-04       Impact factor: 9.867

Review 7.  Inhibition of IL-6 for the treatment of inflammatory diseases.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

8.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.

Authors:  C Lütticken; U M Wegenka; J Yuan; J Buschmann; C Schindler; A Ziemiecki; A G Harpur; A F Wilks; K Yasukawa; T Taga
Journal:  Science       Date:  1994-01-07       Impact factor: 47.728

9.  A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma.

Authors:  K Shuai; G R Stark; I M Kerr; J E Darnell
Journal:  Science       Date:  1993-09-24       Impact factor: 47.728

10.  Decreased c-Src expression enhances osteoblast differentiation and bone formation.

Authors:  M Marzia; N A Sims; S Voit; S Migliaccio; A Taranta; S Bernardini; T Faraggiana; T Yoneda; G R Mundy; B F Boyce; R Baron; A Teti
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

View more
  40 in total

1.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Chikahisa Higuchi; Makoto Hirao; Michio Okamoto; Kota Koizumi; Tokimitsu Morimoto; Hideki Yoshikawa; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

2.  Serum CTX levels and histomorphometric analysis in Src versus RANKL knockout mice.

Authors:  Sunao Takeshita; Toshio Fumoto; Masako Ito; Kyoji Ikeda
Journal:  J Bone Miner Metab       Date:  2017-06-06       Impact factor: 2.626

3.  [Local and systemic bone effects of rheumatoid arthritis].

Authors:  M Rauner; L C Hofbauer; M Aringer
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

4.  Systemic IL-6 Effector Response in Mediating Systemic Bone Loss Following Inhalation of Organic Dust.

Authors:  Adam Wells; Debra J Romberger; Geoffrey M Thiele; Todd A Wyatt; Elizabeth Staab; Art J Heires; Lynell W Klassen; Michael J Duryee; Ted R Mikuls; Anand Dusad; William W West; Dong Wang; Jill A Poole
Journal:  J Interferon Cytokine Res       Date:  2016-11-22       Impact factor: 2.607

5.  LPS-stimulated inflammatory environment inhibits BMP-2-induced osteoblastic differentiation through crosstalk between TLR4/MyD88/NF-κB and BMP/Smad signaling.

Authors:  Ru-Lin Huang; Yuwen Yuan; Gang-Ming Zou; Guangwang Liu; Jun Tu; Qingfeng Li
Journal:  Stem Cells Dev       Date:  2013-11-07       Impact factor: 3.272

6.  Blood vitronectin is a major activator of LIF and IL-6 in the brain through integrin-FAK and uPAR signaling.

Authors:  Matthew P Keasey; Cuihong Jia; Lylyan F Pimentel; Richard R Sante; Chiharu Lovins; Theo Hagg
Journal:  J Cell Sci       Date:  2018-02-02       Impact factor: 5.285

7.  Bone density assessment in a cohort of pediatric patients affected by 22q11DS.

Authors:  A Ficcadenti; F Zallocco; R Neri; L Giovannini; G Tirabassi; G Balercia
Journal:  J Endocrinol Invest       Date:  2015-04-28       Impact factor: 4.256

8.  Long-Term Administration of High-Fat Diet Corrects Abnormal Bone Remodeling in the Tibiae of Interleukin-6-Deficient Mice.

Authors:  Wei Feng; Bo Liu; Di Liu; Tomoka Hasegawa; Wei Wang; Xiuchun Han; Jian Cui; Kimimitsu Oda; Norio Amizuka; Minqi Li
Journal:  J Histochem Cytochem       Date:  2015-09-28       Impact factor: 2.479

9.  Cellular Factor XIIIA Transglutaminase Localizes in Caveolae and Regulates Caveolin-1 Phosphorylation, Homo-oligomerization and c-Src Signaling in Osteoblasts.

Authors:  Shuai Wang; Mari T Kaartinen
Journal:  J Histochem Cytochem       Date:  2015-07-31       Impact factor: 2.479

10.  IGF-I 3' untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts.

Authors:  Spenser S Smith; Catherine B Kessler; Vikram Shenoy; Clifford J Rosen; Anne M Delany
Journal:  Endocrinology       Date:  2012-11-26       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.